Ajax Therapeutics Acquired by Eli Lilly | Healthcare M&A Deal

Eli Lilly has acquired Ajax Therapeutics, a medical devices business in the healthcare sector, for up to $2.3 billion. Eli Lilly acquisitions focus on expanding capabilities in hematology, with Ajax Therapeutics developing therapies aimed at myelofibrosis and polycythemia vera. The Eli Lilly acquires Ajax Therapeutics strategy supports healthcare M&A goals by strengthening its pipeline and improving patient outcomes in serious blood disorders. This strategic acquisition is structured as a merger acquisition and is categorized as a medical devices acquisition, with deal status announced and total consideration up to $2.3 billion.